http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-503736-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94ff2d78578d95d1e8d3a2233c76188d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 1998-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bc8acf5b2438cae071771a3acc0e2cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f186cb79a6af018a6837d4f6b3694fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed96a9667b0c9623373a4ed949b94108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd6c2630301f634a4febc8821e1858bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f04969889cc60d68557088e0ed0671a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b37c275415bf2dd75f29f1fd20cd2e9c |
| publicationDate | 2002-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-503736-A |
| titleOfInvention | Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists |
| abstract | Described are analogs of PGF2a, the naturally occurring Prostaglandin F. The compounds are of formula (I) wherein; R1 is CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)2R5 or tetrazole; wherein R5 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring, and R2 is H or lower alkyl, and X is NR6R7, OR8, SR9, S(O)R9, S(O)2R9, or F; wherein R6, R7 and R8 are selected from H, acyl, alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring and heteroaromatic ring; and wherein R9 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring, and R3 and R4 are independently H, CH3, C2H5, OR10, SR10, or OH, except that both R3 and R4 are not OH; wherein R10 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, aromatic ring, or heteroaromatic ring, R10 having from 1 to 8 member atoms, and Y is (CH2)n; n being an integer from 0 to 3 Z is heterocyclic aliphatic ring, monocyclic heteroaromatic ring, or substituted phenyl when n is 0, 2, or 3; wherein the phenyl substituents are selected from halo, cyano, heteroalkyl, haloalkyl and phenyl; and Z is heterocyclic aliphatic ring or substituted phenyl when n is 1; wherein the phenyl substituents are selected from halo, cyano, heteroalkyl, haloalkyl and phenyl; and wherein heteroalkyl is a saturated or unsaturated chain containing carbon and at least one heteroatom, and Any optical isomer, diastereomer, enantiomer or pharmaceutically acceptable salt or biohydrolyzable amide, ester, or imide. These compounds are useful for the treatment of bone disorders and glaucoma. Divisional filed as 518844 |
| priorityDate | 1997-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.